INTRODUCTION
T follicular helper (T FH ) cells are a subset of CD4 + T cells that help B cells differentiate into antibody-secreting plasmablasts. 1 Along with PD-1, CXCR5 is the canonical T FH marker, binding to CXCL13 to properly migrate within the germinal centers (GCs). There is also a subset of CD4+CXCR5 +PD-1+ T cells in the periphery, which are superior to other CD4 + subsets in their ability to help B cells. [2] [3] [4] Based on functional properties, peripheral CD4+CXCR5+PD-1+ T cells are a putative circulating T FH population, although their precise relation to GC T FH cells is still under investigation.
Defining T FH -like cells in the periphery has been challenging because the transcription factor that promotes T FH differentiation, Bcl-6, is not detectable in protein form in cells outside the GC. [5] [6] [7] [8] Early studies relied only on CXCR5 expression on CD4 + T cells to identify "pT FH " cells. 3, 9 However, subsequent studies determined that both CXCR5 and PD-1 are required to identify functional pT FH memory cells. 5, 6, 10 Human GC T FH cells also express ICOS, CD40L, and SAP and secrete IL-21. These proteins are necessary for T-cell-B-cell colocalization, adhesion, and signaling. 1 Specifically, ICOS is a costimulatory molecule that engages ICOS ligand on B cells, resulting in T-cell proliferation and production of cytokines that further support B-cell differentiation.
11 CD40L must also be expressed on the surface of T FH cells, as its interaction with CD40 on B-cell surfaces is required for GC formation, and directly promotes B-cell proliferation and isotype switching. 12 Circulating CD4+CXCR5+PD-1+ cells express high levels of CD40L and ICOS after stimulation, and thus combinations of these markers are routinely used to identify T FH -like cells in the periphery. 5, 6, 8, 10, [13] [14] [15] In HIV infection, CD4 + T-cell dysfunction occurs early and precedes the absolute loss of CD4 + T cells. [16] [17] [18] T helper cells from HIV-infected individuals express high levels of inhibitory receptors, resulting in a diminished ability to help B cells. 10, [18] [19] [20] [21] [22] [23] [24] [25] The role of T FH -cell dysfunction in the dysregulation of B cells is less clear, but GC T FH -cell populations have been shown to be expanded in both HIV and simian immunodeficiency virus (SIV) infections. 26, 27 This is consistent with B-cell dysregulation observed in HIV-1 infection, which is characterized by hypergammaglobulinemia, altered maturation patterns, and exhausted phenotypes. 28 In this study, we evaluated the frequency, phenotype, and responsiveness of peripheral T FH cells ("pT FH cells," defined as CD4+CXCR5+PD-1+ T cells) in HIV-1-and chronically infected treatment-naive HIV-1+ individuals. In a series of in vitro stimulation assays, we observed that pT FH cells from HIV-infected individuals had decreased maximal responses to superantigen stimulation as measured by their ability to express ICOS and CD40L. These decreased maximal responses in HIV+ subjects did not correlate with clinical aspects of the disease or neutralizing antibody responses. We also show for the first time that HIV-specific and tetanus-specific responses are maintained within the pT FH -cell population in HIV-infected individuals.
METHODS

Human Subjects
Peripheral blood mononuclear cells (PBMCs) from 10 HIV2 and 34 HIV+ individuals were separated from blood samples using a Ficoll-Paque Plus density gradient. PBMCs were cryopreserved and stored in liquid nitrogen in media composed of 90% fetal bovine serum containing 10% dimethyl sulfoxide (DMSO). All HIV+ individuals were treatment-naive, and CD4 + T-cell counts and viral loads were obtained at the time of donation (Table S1 , http://links.lww. com/QAI/A888). The Vanderbilt University School of Medicine's Institutional Review Board approved this study, and all individuals provided written informed consent.
In Vitro Stimulation Assays
Cyropreserved PBMCs were thawed and washed twice in phosphate-buffered saline (PBS) and either stained immediately or cultured for stimulation assays. PBMCs were cultured at 10 million cells per milliliter in R10 media [RPMI 1640 containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 mg/mL penicillin, 50 mg/mL streptomycin, and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (Gibco, Life Technologies)] and costimulated with anti-CD28 and anti-CD49d (1 mL/mL each, from BD). Stimulation conditions included Staphylococcal enterotoxin B (SEB) (1 mg/mL, Sigma), HIV-1 potential T cell epitope Gag peptides (1 mg/mL, NIH AIDS Reagent Program), 29, 30 tetanus toxoid (10 mg/mL, Astarte Biologics), and AT-2-inactivated HIV-1 MN particles (0.53 mg/mL p24, generously provided by Dr. Jeff Lifson). 23, 31, 32 For comparison with SEB and tetanus stimulation, PBMCs were incubated in R10 media alone. As a control for HIV-1 PTE Gag peptide stimulation (suspended in 0.8% DMSO), cells were suspended in R10 media containing 0.8% DMSO. For comparison with HIV-1 MN, PBMCs were incubated with MN control particles containing AT-2-treated microvesicles prepared from matched uninfected cultures, used at a comparable total protein concentration. 23, 31, 32 In all stimulation assays, cells were incubated overnight at 37°C with 5% CO 2 . After 16 hours, cells were removed from the plate, washed twice with PBS, and stained as described below.
Multicolor Flow Cytometry
Surface markers were evaluated using combinations of fluorochrome-conjugated monoclonal antibodies that were each titrated individually for their optimal stain index. PBMCs were stained at 10 million cells per milliliter in 200 mL PBS. All PBMCs were incubated for 10 minutes with an aminereactive viability dye (LIVE/DEAD Aqua, Invitrogen), washed twice, and then stained for 15 minutes at room temperature with combinations of monoclonal antibodies. For ex vivo phenotyping, cells were stained with CD3-AF700 (UCHT1, BD), CD4-PECy5 (RPA-T4, BD), CD8-APC-AF750 (3B5, Invitrogen), CD45RO-PETR (UCHL1, Beckman Coulter), CCR7-BV421 (150503, BD), CXCR5-AF488 (RF8B2, BD), PD-1-PE (EH12.2H7, BioLegend), CD14-V500 (M5E2, BD), and CD19-V500 (HIB19, BD). In vitro phenotyping was performed with combinations of CD3-AF700, CD4-PECy5, CD8-APC-AF750, CD45RO-PETR, CXCR5-AF488, CD14-V500, CD19-V500, ICOS-PE (DX29, BD), CD40L-PE (TRAP1, BD), and PD-1-BV421 (EH12.2H7, BioLegend). All PBMCs were washed twice after staining, fixed with 2% paraformaldehyde, and analyzed on a BD LSR Fortessa (BD Biosciences) at the VMC Flow Cytometry Shared Resource.
Flow cytometry data were analyzed using BD Biosciences FACSDiva Software. In all experiments, forward and side scatter were used to identify lymphocytes, and from that population nonviable CD14 + , CD19 + , and CD8 + cells were excluded from further analysis (Fig. S1 , http://links.lww.com/QAI/A881).
Antibody Neutralization Assays
Neutralization assays were performed using envelopes from clades A, B, and C in the TZM-bl cell-based pseudovirus assay, as previously described. 33 The clade B and C env clones were chosen from standard env panels, 34, 35 and the clade A env clones were isolated from Kenyan sex workers. 36 The env clones chosen for this study represent a range of neutralization sensitivities of transmitted HIV-1 viruses. Plasma samples were titrated 2-fold from 1:20 to 1:2560 and were incubated for 90 minutes at 37°C in the presence of single-round-competent virions (pseudovirus).
The neutralization values reported here are the IC50. Only 30 individuals were evaluated in the antibody neutralization assays because of sample availability.
Spearman rank correlation coefficient rho (r). All tests were 2 tailed and were considered statistically significant at P , 0.05.
RESULTS
Frequency of CD4+CXCR5+PD-1+ T Cells in the Blood of HIV+ and HIV2 Individuals
T follicular helper (T FH ) cells are more frequent in the lymph nodes during HIV and SIV infections compared with lymph nodes from uninfected controls 20, 26, 27, 37 ; however, there are conflicting reports comparing the frequency of circulating T FH -like cells among HIV-infected and HIV-uninfected individuals. 6, 9, 10 We first assessed the expression of the canonical T FH markers, CXCR5 and PD-1, on circulating CD4 + T cells ( (Table S1 , http://links.lww.com/QAI/A888). There was no difference in the frequency of CD4 + cells with dual CXCR5 and PD-1 expression (pT FH cells) between HIV2 and HIV+ individuals, which constituted an average of 2% of CD4 + T cells (Fig. 1B) .
The distribution of pT FH cells within memory T-cell subsets was then evaluated. We distinguished CD4 + memory subsets based on CCR7 and CD45RO expression: T naive (CCR7+CD45RO2), T central memory (T CM ) (CCR7 +CD45RO+), T effector memory (CCR72CD45RO+), and T effector memory cells expressing CD45RA (CCR72CD45RO2) ( Fig. 1C and Fig. S1A , http://links.lww.com/QAI/A881). 38, 39 There were no significant differences between the distribution of CD4 + T-cell memory populations between HIV+ and HIV2 individuals in our cohort (Fig. S1B , http://links.lww. com/QAI/A881), and most pT FH cells had a T CM phenotype (Fig. 1D ). In the absence of stimulation, few pT FH cells expressed CD40L (,5%) or ICOS (,10%) ( 
pT FH Cells From HIV+ Individuals Have Decreased Maximal Responses to In Vitro Stimulation Compared With Those of Healthy Donors
We next compared the ability of pT FH cells from HIV2 and HIV+ individuals to express ICOS and CD40L in response to SEB stimulation (Fig. 2) . The frequency of ICOS expression without stimulation was higher in pT FH cells from HIV+ individuals compared with HIV2 individuals (median 6.5% and 2.2%, respectively, P = 0.0005; Fig. 2A-B ). After stimulation with SEB, the frequency of ICOS-expressing pT FH cells increased dramatically but was lower in HIV+ compared with that in HIV2 subjects (median 51.1% and 63.8%, respectively, P = 0.03; Fig. 2A-B) . Accordingly, the change in the frequency of ICOS expression on pT FH cells in response to potent stimulation was decreased in HIV+ individuals compared with that in HIV2 individuals (P = 0.003; Fig. 2C ). The frequency of CD40L expression on pT FH cells was similar in HIV2 and HIV+ subjects without stimulation (median 2.5% and 1.4%, respectively, P = 0.24; Figs. 2D-E). After SEB stimulation, however, the frequency of CD40L expression on pT FH cells isolated from healthy individuals was higher (64.6%) compared with HIV+ individuals (47.4%; P = 0.002; Figs. 2D-E). Similarly to ICOS, the change in the frequency of CD40L+ expressing pT FH cells in HIV2 individuals was higher than that of HIV+ individuals after SEB stimulation (P = 0.02; Fig. 2F ).
Decreased Maximal pT FH Responses Did Not Correlate With Clinical Aspects of Disease
We evaluated whether expression of T FH surface markers or responsiveness to in vitro stimulation was associated with either clinical aspects of the disease or the T-cell phenotypes of our cohort. We found no correlation between the degree of response to SEB stimulation and viral load, CD4 + T-cell count, or duration of infection (Fig. 3) . Although PD-1 is a marker that identifies T FH cells, it is also a marker of immune exhaustion. We therefore evaluated whether the degree of PD-1 expression on CXCR5+ T cells predicted the ability of these cells to respond to in vitro stimulation. No relationship existed between the MFI of PD-1 on CXCR5+ cells in the HIV + individuals and the ability of these cells to express ICOS or CD40L responses after SEB stimulation.
No Correlation Between pT FH Responses and Antibody Neutralization Breadth
pT FH cells in the blood are capable of stimulating B cells to differentiate into immunoglobulin-secreting plasmablasts.
3,4,6,10 Despite B-cell dysregulation in HIV-1 infection, 20%-30% of HIV+ subjects produce antibodies that are able to neutralize heterologous HIV-1 strains across clades A, B, and C. 33, 40 To assess whether the frequency of pT FH cells or responsiveness to antigenic stimulation correlated with the production of broadly neutralizing antibodies, we analyzed the serum from all HIV+ subjects for the ability to neutralize heterologous HIV-1 envelopes (Fig. 4) . The subjects in our cohort ranged widely (0%-100%) in their ability to neutralize 20 different HIV-1 isolates from clades A, B, and C (Fig. 4) . We found no correlation between the degree of neutralizing antibody breadth and the frequency of pT FH cells (Fig. S4 , http://links.lww.com/QAI/A884). Additionally, we found no correlation between the degree of neutralizing antibody breadth and the frequency or ability of pT FH cells to express ICOS or CD40L after in vitro stimulation with SEB (Fig. 3) .
pT FH Cells From HIV+ Individuals Maintain Recall Antigen-Specific Responses
We next investigated recall antigen-specific responses of pT FH and non-pT FH (defined as CD3 + CD4 + CXCR52) T cells. Because most naive T cells reside in the non-pT FH population, we only assessed memory (CD45RO+) CD4 + T cells in this assay. We performed stimulations with tetanus toxoid, HIV-1 Gag peptides, and inactivated HIV-1 MN to measure antigenspecific responses in HIV+ individuals (Fig. 5, Fig. S3 Responses to Gag peptides as measured by the change in ICOS and CD40L on CD4 + T cells were greater on pT FH cells compared with those of non-pT FH cells in HIV+ individuals (P = 0.002 and P = 0.0003; Figs. 5C and D). There were no significant changes in ICOS or CD40L expression in HIV2 individuals stimulated with Gag peptides (P = 0.34, data not shown). Because most CD4 + T cells are CXCR52, a higher absolute number of CXCR52 cells increased ICOS expression in response to antigen stimulation; however, a higher fraction of CXCR5+PD-1+ cells were antigen specific. These data demonstrate that recall antigen-specific memory pT FH cells are preserved in HIV+ individuals.
We also evaluated responses to AT-2-inactivated HIV-1 MN particles, which contain conformationally intact envelope proteins on their surface. Compared with control particles, MN did not induce changes in ICOS on pT FH cells in HIV2 subjects (P = 0.13). In HIV+ individuals, MN induced changes in ICOS on pT FH cells compared with control particles (P , 0.0001), and responses were greater in memory pT FH cells compared with those of non-pT FH cells (P = 0.02; Fig. S6A , http://links.lww.com/QAI/A886). Changes in CD40L in response to MN, however, were rare (only 12 of 28 subjects in the assay) and weak and did not allow us to accurately compare non-pT FH and pT FH responses (Fig. S6B , http://links.lww.com/QAI/A886). No antigenspecific responses to any of the recall antigens correlated with neutralizing antibody breadth in HIV+ individuals (Fig. S4 , http://links.lww.com/QAI/A884 and data not shown).
Because the core identity markers of pT FH cells, PD-1 and CXCR5, can also go up with activation, we assessed the frequency of pT FH cells before and after stimulation. The median increase in the frequency of pT FH cells in response to SEB stimulation was 1.95%. Stimulation of PBMCs with recall antigens only slightly increased the frequency of pT FH cells (median increase of 0.2% with Gag stimulation; median increase of 0.5% with tetanus stimulation). To further investigate the possibility of CXCR52 cells contributing to our pT FH population after overnight stimulation, we used fluorescenceactivated cell sorting to sort CD4 + T cells into 4 populations based on CXCR5 and PD-1 expression in 4 healthy individuals. Cells that were sorted CXCR52 (regardless of PD-1 expression) became CXCR5+ after SEB stimulation at a frequency of ,2.5% and the MFI of CXCR5 after SEB stimulation never changed (Fig. S7 , http://links.lww.com/QAI/A887 and data not shown). Thus, although we cannot exclude the possibility that a small number of cells we termed "pT FH " in these assays were recently activated T cells, most of this pT FH population expressed CXCR5 and PD-1 before stimulation.
DISCUSSION
Multiple studies have demonstrated pT FH cells are similar to GC T FH cells in their ability to provide B-cell help. [2] [3] [4] [5] [6] 41 We performed an ex vivo phenotypic analysis of pT FH cells in healthy and chronically infected HIV+ individuals, and we assessed the in vitro responses of this cell population to superantigen and recall antigen stimulation. CXCR5+ and PD-1 are currently accepted canonical markers required to identify pT FH cells. 5, 6, 8, 10, [13] [14] [15] Although additional cell markers such as CXCR3, 6 CCR6, 10 and TIGIT+ 42 have been suggested to further discriminate pT FH cells, we focused on CD4 + T cells expressing the main pT FH identifying canonical markers. We evaluated the ability of these cells to respond to various stimuli and identified tetanus-specific and HIV-specific pT FH populations in HIV-infected individuals. We focused on ICOS and CD40L expression of pT FH cells because these surface receptors must engage ICOS ligand and CD40 on the surface of B cells to drive B-cell differentiation to antibody-secreting plasmablasts.
We observed that pT FH cells circulate at similar frequencies in healthy and HIV+ treatment-naive individuals. The frequencies of circulating pT FH cells we measured are in agreement with those measured in a cohort with CD4 + T-cell numbers similar to ours. 9 In separate studies, however, decreased pT FH -cell frequencies were reported in a cohort with a mean CD4 + T-cell count of 320 cells/mm 3 , 10 and increased frequencies were found in a cohort of individuals who were only infected for an average of 3 years (CD4 + T-cell values were not reported). 6 Thus, variability within these cohorts likely explains the variability in measured frequencies of pT FH cells. We also show that the distribution of pT FH cells within T-cell memory compartments in HIV infection is not perturbed by HIV infection and confirm that most pT FH cells reside in the T central memory compartment in both HIV2 and HIV+ individuals. 2, 3, 9 GC T FH cells and pT FH cells isolated from HIV-and SIV-infected individuals are impaired in their ability to provide help necessary for B cells to differentiate into plasmablasts. 9, 10, 19, 20, 26, 27 However, the underlying changes in expression of key surface receptors on pT FH cells required for proper function have not been described. Here, we provide an analysis of the surface expression of ICOS and CD40L in response to stimuli in chronic HIV-1 infection.
We found that after in vitro superantigen stimulation, pT FH cells from HIV-infected individuals expressed less ICOS and CD40L than pT FH cells from HIV-uninfected individuals. This reduced maximal expression of ICOS and CD40L might explain the decreased function of these cells observed in HIV and SIV infections. 9, 10, 19, 20, 26, 27 We attempted to determine correlates of this decreased response. We hypothesized that the MFI of PD-1 expression on pT FH cells would correlate with decreased responses in HIV-infected individuals. Although PD-1 is required for proper T FH -cell function, 43, 44 it is also associated with functional exhaustion of T cells during chronic HIV-1 infection. 18, 45 Blocking PD-1 and PD-L1 has been shown to enhance the ability of T cells to activate B cells in culture 23 and improves the ability of pT FH cells to stimulate B cells to produce IgG in HIV+ but not HIV2 individuals. 19 We found no correlation between PD-1 expression and decreased pT FH -cell responsiveness in HIV-infected individuals. We also did not find a correlation between the responsiveness of pT FH cells with viral load, CD4 + T-cell count, years postinfection, or neutralizing antibody breadth.
Recall antigen-specific pT FH cells have been identified in a few previous studies: tetanus-specific pT FH cells were identified using tetramers in healthy individuals 6 and in HIVinfected individuals, small populations of Gag-specific pT FH cells were identified by CD40L expression and IL-21 secretion. 10 More recently, HIV-specific pT FH cells (identified by IL-21 secretion after in vitro stimulation, and subsequently found to express transcripts for CXCR5, CD40L, and ICOS) were shown to recognize both HIV-1 Gag and env peptides by ELISpot. 41 In agreement with these studies, we found that most recall memory responses reside within the CD4 +CXCR52 population, which makes up most CD4 + T cells. However, the proportion of pT FH cells that increase ICOS or CD40L expression is significantly higher than that of nonpT FH cells in response to HIV Gag peptides and tetanus toxoid in HIV+ individuals. This was also true for ICOS responses to HIV-1 MN in HIV+ individuals, but not CD40L which we were unable to assess accurately because responses were so rare. HIV2 individuals did not respond to Gag or MN stimulation as expected, but did have weak responses to tetanus toxoid stimulation. There was no difference in the frequency of these weak tetanus responses in pT FH compared with non-pT FH cells in HIV2 individuals. It is difficult to make accurate conclusions from these findings because we have no tetanus vaccination records from our study populations. However, the HIV+ individuals are followed very closely and more likely to be up to date on all vaccinations. Our novel findings show that HIV-specific CD4 + T cells are maintained within the pT FH population during chronic infection.
HIV and SIV infections have been shown to drive the expansion of GC T FH cells, 19, 27 but the relationship between the frequencies of GC T FH and peripheral T FH cells is unclear. Recent gene expression and functional studies disagree on precisely which combination of surface receptors identifies T FH -like cells in the periphery; however, there seems to be a consensus that CXCR5 and PD-1 are required for identifying pT FH cells. 5, 6, 10 Our observation of preferential expression of CD40L and ICOS expression on CD4+CXCR5+PD-1+ T cells in response to recall antigens further supports the identification of pT FH cells as a circulating counterpart of GC T FH cells. It is important to note that superantigen and recall antigen stimulation increased the frequency of CXCR5+PD-1+ cells in vitro. This increased frequency could reflect proliferation of pT FH cells or a new population of recently activated T cells. Cell sorting experiments, however, demonstrated that few sorted CXCR52 cells became CXCR5+PD-1+ after short-term superantigen stimulation; thus, most of this population was likely CD4+CXCR5+PD-1+ cells before stimulation. Future studies should recapitulate pT FH phenotypic changes in response to antigen with IL-21 measurement to establish that the trends are the same. We tested many IL-21 antibody clones in intracellular cytokine assays under many stimulation conditions (PMA/ionomycin, anti-CD3/anti-CD28, and SEB) at 4, 6, 24, 48, and 72 hours without obtaining reliable results. Unfortunately, current antibodies to IL-21 protein are poor, making intracellular cytokine assays unable to address this question accurately. 46 The development of new commercially available IL-21 detection kits (of protein or transcript) will be valuable for future single-cell IL-21 research. 46 The generation of HIV-neutralizing antibody responses through vaccination has remained an elusive goal; understanding how naturally infected individuals are able to generate broadly neutralizing antibodies will be critical to our understanding of vaccine-induced immune responses. Here, we analyzed the neutralization breadth of plasma from 30 HIV+ individuals in our cohort. In agreement with previous studies, we did not find a direct correlation between neutralization breadth and the frequency of pT FH cells during chronic HIV infection. 6, 8 We also found no correlation between neutralization breadth and the frequency of ICOS+ pT FH cells. This is in contrast to findings by Locci et al 6 ; however, subjects in that study were grouped into "top" and "low" neutralizers, and statistical correlations were not performed. Despite a lack of correlation during chronic infection, Cohen et al 8 found correlations between the frequency of pT FH cells and broadly neutralizing antibody responses in early infection (0.1-1 year after infection). One interpretation of these data is that during early HIV infection, pT FH responses may not yet be impaired and thus can facilitate the generation of broadly neutralizing antibodies, and these antibody responses can be maintained over the course of chronic infection. Future studies should investigate the responsiveness of pT FH cells to HIV antigens longitudinally from early through chronic HIV infection.
In this study, we describe our efforts to determine the responsiveness of pT FH cells in chronic HIV-1 infection. Specifically, we investigated 2 surface receptors required by T FH cells to provide help to B cells, ICOS and CD40L. We demonstrate that pT FH cells expressed the highest levels of CD40L and ICOS in response to superantigen and recall antigen stimulation compared with CD4+CXCR5+PD-12 T cells and CD4+CXCR52 T cells. We found that the pT FH cells of HIV-infected individuals had impaired ability to increase expression of CD40L and ICOS in response to superantigen stimulation. Despite impaired maximal responses, this cell subset maintained the ability to respond to recall antigens. These results suggest that the evaluation of immune responses of pathogen-specific circulating pT FH cells will be important for future studies of natural infection and immune responses to vaccines.
